QUEBEC CITY, Sept. 3 /CNW Telbec/ - Atrium Innovations Inc. (TSX: ATB), a
leading developer, manufacturer and marketer of science-based and
professionally supported products for the Health and Nutrition industry, today
announced various initiatives to support the development of its Wobenzym(R)
brand in Germany.
Atrium announces that Mucos Pharma, a subsidiary of Atrium, has initiated
the phase out of Wobenzym(R) N in Germany earlier than initially anticipated.
Concurrently, Mucos Pharma is launching a new marketing campaign for
Wobenzym(R) P, a natural enzyme-based product with an active OTC drug
registration. Wobenzym(R) P will be commercialized like its predecessor,
Wobenzym(R) N, as systemic enzyme therapy. As planned, Mucos Pharma intends to
launch a new formulation of Wobenzym(R) to be sold as a food supplement in
Germany and other Western European countries in early 2010.
Atrium will hold a conference call about its Wobenzym(R)
commercialization strategy in Germany on September 3, 2009 at 8:45 a.m.
Eastern time. Participants may access the call by using the following numbers:
1-888-231-8191 or 1-647-427-7450 (international and local calls), conference
number: 28576925. A replay of the call will also be available on Atrium's
website for a period of 30 days.
Atrium Innovations Inc. is a recognized leading developer, manufacturer
and marketer of science-based and professionally supported products for the
Health & Nutrition industry. The Company focuses primarily on growing segments
of the health and nutrition markets which are benefiting from the trends
towards healthy living and the ageing of the population. Atrium markets a
broad portfolio of finished products through its highly specialized sales and
marketing network in more than 35 countries, primarily in North America and
Europe. Atrium has over 800 employees and operates seven manufacturing
facilities. Additional information about Atrium is available on its website at
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with
respect to the Company. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by these forward-looking statements.
The Company considers the assumptions on which these forward-looking
statements are based to be reasonable, but cautions the reader that these
assumptions regarding future events, many of which are beyond its control, may
ultimately prove to be incorrect since they are subject to risks and
uncertainties that affect the Company. For additional information with respect
to these and other factors, see the Company's quarterly and annual filings
with the Canadian securities commissions. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, other than as required
For further information:
For further information: Investor Relations: Mario Paradis, Vice
President and Chief Financial Officer, (418) 652-1116,
email@example.com; Media Relations: Frédéric Tremblay, (514) 844-6665,